SECTION-1: Identification of the substance / mixture and the company / undertaking

Catalogue Number	CS-ZE-30688
Product Name	Vericiguat
CAS No.	1350653-20-1
Category	API
Synonyms	Verquvo; BAY 1021189; Methyl [4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate
Brand	Clearsynth Labs Ltd.
Identified uses	Laboratory Chemicals
Uses advised against	Not available
Company	Clearsynth Labs Ltd. Mumbai, India
Emergency Phone #	+91-22-245045900
REACH No.	Not available

SECTION 2: Hazards identification

Disclaimer: This is sample MSDS. Please email **sales@clearsynth.com** for more details.

2.1 Classification of the substance or mixture-Regulation (EC) No 1272/2008:

Not available

2.2 Label Elements

Signal Word: Warning

Not available

Hazard Statement(s)

Code	Statement
H372	Not available

Precautionary Statement(s)

Code	Statement
P260	Not available
P264	Wash hands thoroughly after handling.
P270	Not available

P319	Get medical help if you feel unwell.
P501	Dispose of contents/container in accordance with local/regional/national/international regulatio

SECTION 3: Composition / information on ingredients

3.1 Substance

Component : Vericiguat
CAS Number : 1350653-20-1
Molecular Formula : C19H16F2N8O2
Molecular Weight : 426.38
Parent Chemical : Vericiguat
Synonyms : Verquvo; BAY 1021189; Methyl [4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate
Concentration : Not available

SECTION 4: First aid measures

Not available

SECTION 5: Firefighting measures

Not available

SECTION 6: Accidental release measures

Not available

SECTION-7: Handling and storage

Not available

SECTION 8: Exposure controls / personal protection

Not available

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Test	Result
Appearance	Off white solid

Test	Result
IR spectrum	Confirms
pH	No data available
Solubility	In DMSO

Property	Value
a) Physical State	No data available
b) Color	No data available
c) Odor	No data available
d) pH	No data available
e) Vapour Pressure	No data available
f) Viscosity	No data available
g) Initial Boiling Point and boiling range	No data available
h) Melting Point / Freezing Point	No data available
i) Auto Ignition Temperature	No data available
j) Flash Point	No data available
k) Explosion Limit, Lower	No data available
l) Explosion Limit, Upper	No data available
m) Decomposition Temperature	No data available
n) Loss on Drying	No data available
o) Relative Density	No data available
p) Solubility (in DMSO)	No data available
q) Oxidizing Properties	No data available

SECTION 10: Stability and reactivity

Not available

SECTION 11: Toxicological information

11.1 Information on toxicological effects

- Acute toxicity: Limited information is available about toxicity in human patients treated with vericiguat. In the clinical trial, doses up to 10 mg have been investigated. In a study of patients with HFpEF, multiple doses of vericiguat 15 mg were investigated without toxicity. However, in the event of an overdose, hypotension may occur. There is no specific antidote for vericiguat toxicity. Symptomatic treatment should be provided. Vericiguat is not removed by hemodialysis due to the high plasma protein binding(98%).
- Skin corrosion/irritation: No data available.
- Serious eye damage/eye irritation: No data available.
- Respiratory or skin sensitization: No data available.
- Germ cell mutagenicity: No data available.
- Carcinogenicity: No data available.
- Reproductive toxicity: No data available.
- STOT-single exposure: No data available.
- STOT-repeated exposure: No data available.
- Aspiration hazard: No data available.

Likely routes of exposure
- No data available.

Symptoms related to the physical, chemical and toxicological characteristics
- Limited information is available about toxicity in human patients treated with vericiguat. In the clinical trial, doses up to 10 mg have been investigated. In a study of patients with HFpEF, multiple doses of vericiguat 15 mg were investigated without toxicity. However, in the event of an overdose, hypotension may occur. There is no specific antidote for vericiguat toxicity. Symptomatic treatment should be provided. Vericiguat is not removed by hemodialysis due to the high plasma protein binding(98%).

SECTION 12: Ecological information

Not available

SECTION 13: Disposal considerations

Not available

SECTION 14: Transport information

Not available

SECTION 15: Regulatory information

Not available

SECTION 16: Other information

Not available

DISCLAIMER

This MSDS is system-generated. Please verify and confirm all data, statements, and values with the Support Team before use or distribution.